Drugs / E-58425
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03108482 | Mar → Nov 2017 | — | Esteve Pharmaceuticals, S.A. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E-58425 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03108482 ↗ |
| Known as | Co-crystal E-58425 | “Co-crystal E-58425 (Tramadol/Celecoxib): Two immediate release oral over-encapsulated tablets of 100 mg, every 12 hours for 48 hours.” NCT03108482 ↗ |
| Known as | CTC | “Co-crystal of tramadol-celecoxib (CTC) has improved efficacy and comparable tolerability versus immediate-release tramadol 50 mg alone, with a similar tramadol daily dose, over...” PMID 40314885 ↗ May 2025 |
| Route | Oral | “Two immediate release oral over-encapsulated tablets of 100 mg, every 12 hours for 48 hours.” NCT03108482 ↗ |